- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00002717
Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for ovarian or peritoneal cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of paclitaxel plus cisplatin in treating patients who have residual disease after surgery to remove stage III or stage IV ovarian cancer or primary peritoneal cancer.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
OBJECTIVES: I. Compare progression free and overall survival and frequency of response in patients with suboptimal stage III or IV ovarian epithelial cancer or primary peritoneal cancer treated with a 24 hour vs 96 hour infusion of paclitaxel (TAX) followed by cisplatin. II. Determine the incidence and severity of adverse events, including catheter complications and drug toxicity, for the 96 hour infusion of TAX. III. Compare the relationship between plasma TAX concentrations, toxicity, and response to both infusion schedules in this patient population.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center and measurable disease (yes vs no). Patients are randomized into one of two treatment arms. Arm I: Patients receive paclitaxel IV continuously over 24 hours followed by cisplatin IV over 2 hours. Arm II: Patients receive paclitaxel IV continuously over 96 hours followed by cisplatin IV over 2 hours. Treatment repeats every 3 weeks for 6 courses.
PROJECTED ACCRUAL: A total of 324 patients will be accrued for this study over 4.5 years.
Studietype
Inschrijving (Verwacht)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35294
- University of Alabama Comprehensive Cancer Center
-
-
California
-
Los Angeles, California, Verenigde Staten, 90033-0800
- USC/Norris Comprehensive Cancer Center
-
Los Angeles, California, Verenigde Staten, 90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
Orange, California, Verenigde Staten, 92868
- Chao Family Comprehensive Cancer Center
-
Palo Alto, California, Verenigde Staten, 94304
- Women's Cancer Center
-
-
Colorado
-
Denver, Colorado, Verenigde Staten, 80262
- University of Colorado Cancer Center
-
-
District of Columbia
-
Washington, District of Columbia, Verenigde Staten, 20307-5000
- Walter Reed Army Medical Center
-
Washington, District of Columbia, Verenigde Staten, 20007
- Vincent T. Lombardi Cancer Research Center, Georgetown University
-
-
Florida
-
Tampa, Florida, Verenigde Staten, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Emory University Hospital - Atlanta
-
-
Hawaii
-
Honolulu, Hawaii, Verenigde Staten, 96813
- MBCCOP - Hawaii
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60612
- Rush-Presbyterian-St. Luke's Medical Center
-
Chicago, Illinois, Verenigde Staten, 60637
- University of Chicago Cancer Research Center
-
Decatur, Illinois, Verenigde Staten, 62526
- CCOP - Central Illinois
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46202-5265
- Indiana University Cancer Center
-
-
Iowa
-
Iowa City, Iowa, Verenigde Staten, 52242
- University of Iowa Hospitals and Clinics
-
-
Kentucky
-
Lexington, Kentucky, Verenigde Staten, 40536-0084
- Albert B. Chandler Medical Center, University of Kentucky
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- Johns Hopkins Oncology Center
-
-
Massachusetts
-
Worcester, Massachusetts, Verenigde Staten, 01655
- University of Massachusetts Memorial Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48106
- CCOP - Ann Arbor Regional
-
Detroit, Michigan, Verenigde Staten, 48201
- Barbara Ann Karmanos Cancer Institute
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55455
- University of Minnesota Cancer Center
-
-
Mississippi
-
Jackson, Mississippi, Verenigde Staten, 39216-4505
- University of Mississippi Medical Center
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64131
- CCOP - Kansas City
-
Saint Louis, Missouri, Verenigde Staten, 63110
- Washington University School of Medicine
-
-
New Jersey
-
Camden, New Jersey, Verenigde Staten, 08103
- Cooper Hospital/University Medical Center
-
-
New York
-
Albany, New York, Verenigde Staten, 12208
- Cancer Center of Albany Medical Center
-
Brooklyn, New York, Verenigde Staten, 11203
- State University of New York Health Science Center at Brooklyn
-
New York, New York, Verenigde Staten, 10021
- Memorial Sloan-Kettering Cancer Center
-
Rochester, New York, Verenigde Staten, 14642
- University of Rochester Cancer Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Verenigde Staten, 27599-7295
- Lineberger Comprehensive Cancer Center, UNC
-
Durham, North Carolina, Verenigde Staten, 27710
- Duke Comprehensive Cancer Center
-
Winston-Salem, North Carolina, Verenigde Staten, 27157-1082
- Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45219
- Barrett Cancer Center, The University Hospital
-
Cleveland, Ohio, Verenigde Staten, 44195
- Cleveland Clinic Cancer Center
-
Cleveland, Ohio, Verenigde Staten, 44106-5065
- Ireland Cancer Center
-
Columbus, Ohio, Verenigde Staten, 43210
- Arthur G. James Cancer Hospital - Ohio State University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73190
- University of Oklahoma College of Medicine
-
-
Pennsylvania
-
Abington, Pennsylvania, Verenigde Staten, 19001
- Abington Memorial Hospital
-
Hershey, Pennsylvania, Verenigde Staten, 17033
- Milton S. Hershey Medical Center
-
Philadelphia, Pennsylvania, Verenigde Staten, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107
- Pennsylvania Hospital
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- University of Pennsylvania Cancer Center
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107
- Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29425-0721
- Medical University of South Carolina
-
Spartanburg, South Carolina, Verenigde Staten, 29303
- CCOP - Upstate Carolina
-
-
Tennessee
-
Memphis, Tennessee, Verenigde Staten, 38117
- CCOP - Baptist Cancer Institute
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75235-9154
- Simmons Cancer Center - Dallas
-
Houston, Texas, Verenigde Staten, 77030
- University of Texas - MD Anderson Cancer Center
-
-
Virginia
-
Charlottesville, Virginia, Verenigde Staten, 22908
- Cancer Center, University of Virginia HSC
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98195-6043
- University Of Washington Medical Center
-
Tacoma, Washington, Verenigde Staten, 98405
- Tacoma General Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
DISEASE CHARACTERISTICS: Histologically confirmed primary ovarian epithelial cancer or primary peritoneal cancer Suboptimal residual disease within 6 weeks of laparotomy with maximum resection Stage III residual retroperitoneal disease greater than 1 cm and no greater than 1 cm residual intraperitoneal disease OR Stage IV disease The following histologies are eligible: Serous adenocarcinoma Malignant Brenner's tumor Mucinous adenocarcinoma Endometrioid adenocarcinoma Undifferentiated carcinoma Clear cell adenocarcinoma Mixed epithelial carcinoma Transitional cell carcinoma Adenocarcinoma not otherwise specified Measurable disease not required Cytologic confirmation of malignant pleural effusion required if sole basis of entry No borderline (low malignant potential) carcinoma No unclassified ovarian cancer, i.e., thought to be of ovarian origin but unexplored or unable to verify tumor arising from ovarian stroma
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: GOG 0-2 Hematopoietic: WBC at least 3,000/mm3 Absolute granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times normal AST, ALT, and GGT no greater than 3 times normal Alkaline phosphatase no greater than 3 times normal LDH no greater than 3 times normal No acute hepatitis Renal: Creatinine no greater than 2 mg/dL Cardiovascular: No history of congestive heart failure No history of unstable angina No myocardial infarction within 6 months Other: No severe infection, including septicemia No severe gastrointestinal bleeding No history of second malignancy within 5 years except nonmelanomatous skin cancer Not pregnant or nursing Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior cytotoxic chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery: See Disease Characteristics No more than 6 weeks since staging laparotomy and primary cytoreductive surgery
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
Medewerkers en onderzoekers
Sponsor
Medewerkers
Publicaties en nuttige links
Algemene publicaties
- Farley JH, Tian C, Rose GS, Brown CL, Birrer M, Maxwell GL. Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials. Cancer. 2009 Sep 15;115(18):4210-7. doi: 10.1002/cncr.24482.
- Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, Armstrong DK. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer. 2009 Mar 1;115(5):1028-35. doi: 10.1002/cncr.24084.
- Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP; Gynecologic Oncology Group. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2008 Jan 1;26(1):83-9. doi: 10.1200/JCO.2007.13.1953. Epub 2007 Nov 19.
- Spriggs DR, Brady MF, Vaccarello L, Clarke-Pearson DL, Burger RA, Mannel R, Boggess JF, Lee RB, Hanly M. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Oct 1;25(28):4466-71. doi: 10.1200/JCO.2006.10.3846.
- Spriggs DR, Brady M, Rubin S, et al.: A phase III randomized trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected stage III or stage IV epithelial ovarian cancer (GOG162). [Abstract] J Clin Oncol 22 (Suppl 14): A-5004, 450s, 2004.
- Rose PG, Java JJ, Salani R, Geller MA, Secord AA, Tewari KS, Bender DP, Mutch DG, Friedlander ML, Van Le L, Method MW, Hamilton CA, Lee RB, Wenham RM, Guntupalli SR, Markman M, Muggia FM, Armstrong DK, Bookman MA, Burger RA, Copeland LJ. Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. Obstet Gynecol. 2019 Feb;133(2):245-254. doi: 10.1097/AOG.0000000000003086. Erratum In: Obstet Gynecol. 2019 Apr;133(4):830.
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
- stadium III eierstokepitheelkanker
- stadium IV eierstokepitheelkanker
- primaire peritoneale holtekanker
- ovarium sereus cystadenocarcinoom
- ovarium ongedifferentieerd adenocarcinoom
- ovarium clear cell cystadenocarcinoom
- ovarium endometrioïde adenocarcinoom
- ovarium slijmvlies cystadenocarcinoom
- ovarium gemengd epitheelcarcinoom
- Brenner-tumor
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per histologisch type
- Neoplasmata
- Urogenitale neoplasmata
- Neoplasmata per site
- Carcinoom
- Neoplasmata, glandulair en epitheel
- Genitale neoplasmata, vrouwelijk
- Endocriene systeemziekten
- Ovariële ziekten
- Adnexale ziekten
- Gonadale aandoeningen
- Endocriene klierneoplasmata
- Ovariumneoplasmata
- Carcinoom, ovariumepitheel
- Moleculaire mechanismen van farmacologische werking
- Antineoplastische middelen
- Tubuline-modulatoren
- Antimitotische middelen
- Mitose modulatoren
- Antineoplastische middelen, fytogeen
- Paclitaxel
- Cisplatine
Andere studie-ID-nummers
- CDR0000064554
- GOG-0162
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Eierstokkanker
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)WervingAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
University of Southern CaliforniaNational Cancer Institute (NCI)WervingLokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterIngetrokkenProstaat Adenocarcinoom | Prostaatkanker stadium II AJCC v8 | Stadium IIC prostaatkanker AJCC v8 | Stadium IIA prostaatkanker AJCC v8 | Stadium IIB prostaatkanker AJCC v8 | Fase I Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
Klinische onderzoeken op cisplatine
-
Centre Oscar LambretNational Cancer Institute, FranceBeëindigdPlaveiselcelcarcinoom van de slokdarmFrankrijk
-
Third Military Medical UniversityOnbekendBehandeling | Diagnose stellen van ziekten | Longadenocarcinoom, stadium I | Circulerende tumorcellenChina